Drug intelligence / Profile preview

uridine polyphosphate peptide

Development stage: Unknown
Lead developer: Hefei Yongsheng Pharmaceutical
Modality: Peptides
Administration: Intravenous

Overview

Uridine polyphosphate peptide (brand name Xidike) is an immunomodulatory biologic developed by Hefei Yongsheng Pharmaceutical. It is a complex mixture of uridine polyphosphates and peptides extracted from human urine. The drug is primarily used as an adjuvant therapy in combination with chemotherapy for patients with advanced breast cancer and non-small cell lung cancer (NSCLC). Its clinical utility lies in its ability to enhance the therapeutic efficacy of chemotherapeutic agents while simultaneously reducing hematological toxicities, such as leukopenia, and boosting the patient's immune function.

Brand names: Xidike
Other names: uridine polyphosphate peptide injection喜滴克

Beyond the preview

Go deeper on uridine polyphosphate peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on uridine polyphosphate peptide.

Explore the full profile